These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 15582006)

  • 21. Comparative effectiveness of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer.
    Du XL; Parikh RC; Lairson DR; Giordano SH; Cen P
    Med Oncol; 2013 Mar; 30(1):440. PubMed ID: 23307252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PARP inhibition: A promising therapeutic target in ovarian cancer.
    Musella A; Marchetti C; Gasparri ML; Salerno L; Casorelli A; Domenici L; Imperiale L; Ruscito I; Abdul Halim T; Palaia I; Di Donato V; Pecorini F; Monti M; Muzii L; Panici PB
    Cell Mol Biol (Noisy-le-grand); 2015 Oct; 61(6):44-61. PubMed ID: 26518896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pazopanib: an alternative in taxane-resistant cutaneous angiosarcoma.
    Fujita M; Endo Y; Fujisawa A; Tanioka M; Kabashima K; Miyachi Y
    Eur J Dermatol; 2014; 24(2):267-8. PubMed ID: 24682601
    [No Abstract]   [Full Text] [Related]  

  • 24. Taxane refractory prostate cancer.
    Mathew P; Dipaola R
    J Urol; 2007 Sep; 178(3 Pt 2):S36-41. PubMed ID: 17644120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single nedaplatin treatment as salvage chemotherapy for platinum/taxane-resistant/refractory epithelial ovarian, tubal and peritoneal cancers.
    Goto T; Takano M; Ohishi R; Iwasa N; Shimizu M; Hasegawa K; Nagao S; Fujiwara K
    J Obstet Gynaecol Res; 2010 Aug; 36(4):764-8. PubMed ID: 20666942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma: A Clinical Implication of In vitro Drug Resistance Assay.
    Matsuo K; Bond VK; Im DD; Rosenshein NB
    Am J Clin Oncol; 2010 Aug; 33(4):358-63. PubMed ID: 19875949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer.
    Modi S; DiGiovanna MP; Lu Z; Moskowitz C; Panageas KS; Van Poznak C; Hudis CA; Norton L; Tan L; Stern DF; Carter D; Seidman AD
    Cancer Invest; 2005; 23(6):483-7. PubMed ID: 16203655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6).
    Wagner U; du Bois A; Pfisterer J; Huober J; Loibl S; Lück HJ; Sehouli J; Gropp M; Stähle A; Schmalfeldt B; Meier W; Jackisch C;
    Gynecol Oncol; 2007 Apr; 105(1):132-7. PubMed ID: 17161453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer.
    Nishio S; Sugiyama T; Shouji T; Yoshizaki A; Kitagawa R; Ushijima K; Kamura T
    Gynecol Oncol; 2007 Aug; 106(2):342-7. PubMed ID: 17499346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is single-agent chemotherapy acceptable in platinum-sensitive relapsed ovarian cancer?
    Abou-Jawde RM; Oberoi SS
    J Clin Oncol; 2008 May; 26(15):2602-3; author reply 2603. PubMed ID: 18487582
    [No Abstract]   [Full Text] [Related]  

  • 31. Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance.
    Ferriss JS; Kim Y; Duska L; Birrer M; Levine DA; Moskaluk C; Theodorescu D; Lee JK
    PLoS One; 2012; 7(2):e30550. PubMed ID: 22348014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypoxia and Noncoding RNAs in Taxane Resistance.
    Pucci P; Rescigno P; Sumanasuriya S; de Bono J; Crea F
    Trends Pharmacol Sci; 2018 Aug; 39(8):695-709. PubMed ID: 29891252
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy.
    Hanker LC; Loibl S; Burchardi N; Pfisterer J; Meier W; Pujade-Lauraine E; Ray-Coquard I; Sehouli J; Harter P; du Bois A;
    Ann Oncol; 2012 Oct; 23(10):2605-2612. PubMed ID: 22910840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. βIII-Tubulin: biomarker of taxane resistance or drug target?
    Karki R; Mariani M; Andreoli M; He S; Scambia G; Shahabi S; Ferlini C
    Expert Opin Ther Targets; 2013 Apr; 17(4):461-72. PubMed ID: 23379899
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Taxane-resistant lymphoepithelial-like carcinoma: excellent response to VIP chemotherapy.
    Duffy AG; Wyse G; Horgan AM; O'Keefe M; O'Reilly S; Breathnach OS
    Ir J Med Sci; 2006; 175(3):64-5. PubMed ID: 17073251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-utility analysis of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer.
    Lairson DR; Parikh RC; Cormier JN; Du XL
    Value Health; 2014; 17(1):34-42. PubMed ID: 24438715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy.
    Dumontet C; Isaac S; Souquet PJ; Bejui-Thivolet F; Pacheco Y; Peloux N; Frankfurter A; Luduena R; Perol M
    Bull Cancer; 2005 Feb; 92(2):E25-30. PubMed ID: 15749640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity.
    McWhinney-Glass S; Winham SJ; Hertz DL; Yen Revollo J; Paul J; He Y; Brown R; Motsinger-Reif AA; McLeod HL;
    Clin Cancer Res; 2013 Oct; 19(20):5769-76. PubMed ID: 23963862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer.
    Obata H; Yahata T; Quan J; Sekine M; Tanaka K
    Anticancer Res; 2006; 26(3B):2227-32. PubMed ID: 16821592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Taxane effect in a bladder washing.
    Dustin SM; Jeffus SK; Stelow EB
    Diagn Cytopathol; 2015 Jan; 43(1):32-3. PubMed ID: 24644138
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.